A patient with human immunodeficiency virus-1 infection presented with sub-acute liver failure, temporally related to commencement of an antiretroviral therapy regimen containing dolutegravir (Triumeq). The patient was not a carrier of HLA-B5701, and abacavir hypersensitivity was unlikely. We believe this is the first report of severe dolutegravir-related hepatotoxicity resulting in sub-acute liver failure and transplantation and highlights a potential need for closer monitoring after drug initiation.
Guimarães CavalcantiMMarcello de Araujo-NetoJ andMauro PeraltaJ.Schistosomiasis: clinical management of liver disease. Clin Liv Dis2015;
6: 59–62.
2.
RutherfordGW andHorvathH.Dolutegravir plus two nucleoside reverse transcriptase inhibitors versus efavirenz plus two nucleoside reverse transcriptase inhibitors as initial antiretroviral therapy for people with HIV: a systematic review. PLoS One2016;
11: e0162775.
3.
WalmsleySLAntelaAClumeckNet al.
Dolutegravir plus Abacavir-Lamivudine for the treatment of HIV-1 infection (SINGLE study). NEJM2013;
369: 1807–1818.
4.
OrellCet al. Superior efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) compared with ritonavir (RTV) boosted atazanavir (STV) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naïve women with HIV-1 infection (ARIA study). Presented at International AIDS Conference (IAC), 18–22 July 2016, abstract no. 10215, Durban, South Africa.
5.
NunezM.Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol2006;
44: S132–S139.
6.
LucenaMIAndradeRJKaplowitzNet al.
Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology2009;
49: 2001–2009.
7.
RussoMWGalankoJAShresthaRet al.
Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl2004;
10: 1018–1023.
8.
MallalSPhillipsECarosiGet al.
HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med2008;
358: 568–579.
9.
MonshiMMFaulknerLGibsonAet al.
Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology2013;
57: 727–739.
10.
SulkowskiMSThomasDLChaissonREet al.
Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA2000;
283: 74–80.
11.
LeeWMHynanLSRossaroLet al.
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology2009;
137: 856–864.
